Cited by 318Glioma Diagnosis and TreatmentAdvanced MRI Techniques and ApplicationsMetabolomics and Mass Spectrometry Studies

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy

Open access

Pope, Whitney B., Prins, Robert M., Albert Thomas, M., Nagarajan, Rajakumar, Yen, Katharine E., Bittinger, Mark A., Salamon, Noriko, Chou, Arthur P., Yong, William H., Soto, Horacio, Wilson, Neil, Driggers, Edward, Jang, Hyun G., Su, Shinsan M., Schenkein, David P., Lai, Albert, Cloughesy, Timothy F., Kornblum, Harley I., Wu, Hong, Fantin, Valeria R., Liau, Linda M.·2012·Journal of Neuro-Oncology

DOI 10.1007/s11060-011-0737-8PMC PMC3650613

Open this paper in CoChat — free account

Abstract

Mutations of the isocitrate dehydrogenase 1 and 2 genes (IDH1 and IDH2) are commonly found in primary brain cancers. We previously reported that a novel enzymatic activity of these mutations results in the production of the putative oncometabolite, R(-)-2-hydroxyglutarate (2-HG). Here we investigated the ability of magnetic resonance spectroscopy (MRS) to detect 2-HG production in order to non-invasively identify patients with IDH1 mutant brain tumors. Patients with intrinsic glial brain tumors (n = 27) underwent structural and spectroscopic magnetic resonance imaging prior to surgery. 2-HG levels from MRS data were quantified using LC-Model software, based upon a simulated spectrum obtained from a GAMMA library added to the existing prior knowledge database. The resected tumors were then analyzed for IDH1 mutational status by genomic DNA sequencing, Ki-67 proliferation index by immunohistochemistry, and concentrations of 2-HG and other metabolites by liquid chromatography-mass spectrometry (LC-MS). MRS detected elevated 2-HG levels in gliomas with IDH1 mutations compared to those with wild-type IDH1 (P = 0.003). The 2-HG levels measured in vivo with MRS were significantly correlated with those measured ex vivo from the corresponding tumor samples using LC-MS (r (2) = 0.56; P = 0.0001). Compared with wild-type tumors, those with IDH1 mutations had elevated choline (P = 0.01) and decreased glutathione (P = 0.03) on MRS. Among the IDH1 mutated gliomas, quantitative 2-HG values were correlated with the Ki-67 proliferation index of the tumors (r ( 2 ) = 0.59; P = 0.026). In conclusion, water-suppressed proton ((1)H) MRS provides a non-invasive measure of 2-HG in gliomas, and may serve as a potential biomarker for patients with IDH1 mutant brain tumors. In addition to 2-HG, alterations in several other metabolites measured by MRS correlate with IDH1 mutation status.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1007/s11060-011-0737-8

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Self-citation
Estimation of metabolite concentrations from localized in vivo proton NMR spectra
Provencher, S. W. (1993) · Magnetic Resonance in Medicine · doi:10.1002/mrm.1910300604 · Cited by 3,659
Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer
WISEMAN, H., & HALLIWELL, B. (1996) · Biochemical Journal · doi:10.1042/bj3130017 · Cited by 2,345
The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
Self-citation
Spatial Localization in NMR Spectroscopy in Vivo
Bottomley, P. A. (1987) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1987.tb32915.x · Cited by 1,382
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas
Hartmann, C. J., Meyer, J., Balß, J., Capper, D., Mueller, W. C., Christians, A., Felsberg, J., Wolter, M., Mawrin, C., Wick, W., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0561-9 · Cited by 1,163

Show all 32 references

Research works printed but not linked: 1

Ducray F, Marie Y, Sanson M (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(21):2248 author reply 9 · DOI

Sorted by citations

Items 101–200 of 318

Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas
Juratli, T. A., Peitzsch, M., Geiger, K. D., Schackert, G., Eisenhofer, G., & Krex, D. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not006 · Cited by 40
Clinical Imaging for Diagnostic Challenges in the Management of Gliomas: A Review
Bonm, A. V., Ritterbusch, R., Throckmorton, P., & Graber, J. J. (2020) · Journal of Neuroimaging · doi:10.1111/jon.12687 · Cited by 40
Non-Invasive Prediction of IDH Mutation in Patients with Glioma WHO II/III/IV Based on F-18-FET PET-Guided In Vivo 1H-Magnetic Resonance Spectroscopy and Machine Learning
Bumes, E., Wirtz, F.-P., Fellner, C., Grosse, J., Hellwig, D., Oefner, P. J., Häckl, M., Linker, R. A., Proescholdt, M. A., Schmidt, N. O., et al. (2020) · Cancers · doi:10.3390/cancers12113406 · Cited by 39
Study of metabonomic profiles of human esophageal carcinoma by use of high-resolution magic-angle spinning 1H NMR spectroscopy and multivariate data analysis
Yang, Y., Wang, L., Wang, S., Liang, S., Chen, A., Tang, H., Chen, L., & Deng, F. (2013) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-013-6774-8 · Cited by 38
Advances in Magnetic Resonance Imaging and Positron Emission Tomography Imaging for Grading and Molecular Characterization of Glioma
Chung, C. D., Metser, U., & Ménard, C. M. (2015) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2015.02.002 · Cited by 38
Detection of 2‐hydroxyglutarate in brain tumors by triple‐refocusing MR spectroscopy at 3T in vivo
An, Z., Ganji, S., Tiwari, V., Pinho, M. C., Patel, T., Barnett, S. L., Pan, E., Mickey, B., Maher, E. A., & Choi, C. (2016) · Magnetic Resonance in Medicine · doi:10.1002/mrm.26347 · Cited by 38
Magnetic resonance spectroscopy for the study of cns malignancies
Ruiz‐Rodado, V., Brender, J., Cherukuri, M. K., Gilbert, M. R., & Larion, M. (2020) · Progress in Nuclear Magnetic Resonance Spectroscopy · doi:10.1016/j.pnmrs.2020.11.001 · Cited by 37
Molecular Imaging of Metabolic Reprograming in Mutant IDH Cells
Viswanath, P., Chaumeil, M. M., & Ronen, S. M. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00060 · Cited by 38
Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutantIDHglioma patients
Jafari‐Khouzani, K., Loebel, F., Bogner, W., Rapalino, O., González, R. G., Gerstner, E. R., Chi, A. S., Batchelor, T. T., Rosen, B. R., Unkelbach, J., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now100 · Cited by 37
11C-methinine uptake correlates with MGMT promoter methylation in nonenhancing gliomas
Okita, Y., Nonaka, M., Shofuda, T., Kanematsu, D., Yoshioka, E., Kodama, Y., Mano, M., Nakajima, S., & Kanemura, Y. (2014) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2014.08.004 · Cited by 36
In-VivoProton Magnetic Resonance Spectroscopy of 2-Hydroxyglutarate in Isocitrate Dehydrogenase-Mutated Gliomas: A Technical Review for Neuroradiologists
Kim, H., Kim, S., Lee, H. H., & Heo, H. (2016) · Korean Journal of Radiology · doi:10.3348/kjr.2016.17.5.620 · Cited by 36
Non‐water‐suppressed short‐echo‐time magnetic resonance spectroscopic imaging using a concentric ring k‐space trajectory
Emir, U. E., Burns, B. L., Chiew, M., Jezzard, P., & Thomas, M. A. (2017) · NMR in Biomedicine · doi:10.1002/nbm.3714 · Cited by 36
Optical Analysis of Glioma: Fourier-Transform Infrared Spectroscopy Reveals the IDH1 Mutation Status
Uckermann, O., Juratli, T. A., Galli, R., Conde, M., Wiedemuth, R., Krex, D., Geiger, K. D., Temme, A., Schackert, G., Koch, E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1795 · Cited by 36
Imaging Manifestations of the Leukodystrophies, Inherited Disorders of White Matter
Yang, E., & Prabhu, S. P. (2014) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2013.11.008 · Cited by 35
Echo‐planar spectroscopic imaging with dual‐readout alternated gradients (DRAG‐EPSI) at 7 T: Application for 2‐hydroxyglutarate imaging in glioma patients
An, Z., Tiwari, V., Ganji, S., Baxter, J. D., Levy, M. L., Pinho, M. C., Pan, E., Maher, E. A., Patel, T., Mickey, B., et al. (2017) · Magnetic Resonance in Medicine · doi:10.1002/mrm.26884 · Cited by 35
False-Positive Measurement at 2-Hydroxyglutarate MR Spectroscopy in Isocitrate Dehydrogenase Wild-Type Glioblastoma: A Multifactorial Analysis
Suh, C. H., Kim, H. S., Paik, W., Choi, C., Ryu, K. H., Kim, D., Woo, D., Park, J. E., Jung, S. C., Choi, C. G., et al. (2019) · Radiology · doi:10.1148/radiol.2019182200 · Cited by 34
Identification ofIDHandTERTpmutation status using1H‐MRS in 112 hemispheric diffuse gliomas
Öztürk-Işık, E., Cengiz, S. D., Özcan, A., Yakıcıer, C., Danyeli, A. E., Pamir, M. N., Özduman, K., & Di̇nçer, A. (2019) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.26964 · Cited by 36
2-Hydroxyglutarate as a Magnetic Resonance Biomarker for Glioma Subtyping
Esmaeili, M., Vettukattil, R., & Bathen, T. F. (2013) · Translational Oncology · doi:10.1593/tlo.12424 · Cited by 35
Classification of brain tumor isocitrate dehydrogenase status using MRI and deep learning
Nalawade, S. S., Murugesan, G. K., Vejdani‐Jahromi, M., Fisicaro, R. A., Yogananda, C. G. B., Wagner, B. C., Mickey, B., Maher, E. A., Pinho, M. C., Fei, B., et al. (2019) · Journal of medical imaging · doi:10.1117/1.jmi.6.4.046003 · Cited by 34
Neomorphic mutations create therapeutic challenges in cancer
Takiar, V., Ip, C. K. M., Gao, M., Mills, G. B., & Cheung, L. W. T. (2016) · Oncogene · doi:10.1038/onc.2016.312 · Cited by 33
IDH1 Mutation and World Health Organization 2016 Diagnostic Criteria for Adult Diffuse Gliomas
Tateishi, K., Wakimoto, H., & Cahill, D. P. (2017) · Neurosurgery · doi:10.1093/neuros/nyx247 · Cited by 33
Metabolite-cycled density-weighted concentric rings k-space trajectory (DW-CRT) enables high-resolution 1 H magnetic resonance spectroscopic imaging at 3-Tesla
Steel, A., Chiew, M., Jezzard, P., Voets, N., Plaha, P., Thomas, M. A., Stagg, C. J., & Emir, U. E. (2018) · Scientific Reports · doi:10.1038/s41598-018-26096-y · Cited by 33
Amide Proton Transfer Imaging in Predicting Isocitrate Dehydrogenase 1 Mutation Status of Grade II/III Gliomas Based on Support Vector Machine
Han, Y., Wang, W., Yang, Y., Sun, Y., Xiao, G., Tian, Q., Zhang, J., Cui, G., & Yan, L. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00144 · Cited by 32
Deep learning‐based target metabolite isolation and big data‐driven measurement uncertainty estimation in proton magnetic resonance spectroscopy of the brain
Lee, H. H., & Kim, H. (2020) · Magnetic Resonance in Medicine · doi:10.1002/mrm.28234 · Cited by 35
Tumor Microenvironment-Derived Metabolites: A Guide to Find New Metabolic Therapeutic Targets and Biomarkers
García‐Cañaveras, J. C., & Lahoz, A. (2021) · Cancers · doi:10.3390/cancers13133230 · Cited by 33
Imaging and treatment of brain tumors through molecular targeting: Recent clinical advances
Zaccagna, F., Grist, J. T., Quartuccio, N., Riemer, F., Fraioli, F., Caracò, C., Halsey, R., Aldalilah, Y., Cunningham, C. H., Massoud, T. F., et al. (2021) · European Journal of Radiology · doi:10.1016/j.ejrad.2021.109842 · Cited by 33
MRI-Based Radiomics Combined with Deep Learning for Distinguishing IDH-Mutant WHO Grade 4 Astrocytomas from IDH-Wild-Type Glioblastomas
Hosseini, S. A., Hosseini, E., Hajianfar, G., Shiri, I., Servaes, S., Rosa‐Neto, P., de Godoy, L. L., Nasrallah, M. P., O’Rourke, D. M., Mohan, S., et al. (2023) · Cancers · doi:10.3390/cancers15030951 · Cited by 32
Radiomics, Metabolic, and Molecular MRI for Brain Tumors
Kickingereder, P., & Andronesi, O. C. (2018) · Seminars in Neurology · doi:10.1055/s-0037-1618600 · Cited by 31
MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma
Molloy, A. R., Najac, C., Viswanath, P., Lakhani, A., Subramani, E., Batsios, G., Radoul, M., Gillespie, A. M., Pieper, R. O., & Ronen, S. M. (2020) · Theranostics · doi:10.7150/thno.47317 · Cited by 32
Imaging of Central Nervous System Tumors Based on the 2016 World Health Organization Classification
Ly, I., Wen, P. Y., & Huang, R. Y. (2019) · Neurologic Clinics · doi:10.1016/j.ncl.2019.08.004 · Cited by 30
Challenges and opportunities for advanced neuroimaging of glioblastoma
Henssen, D. J. H. A., Meijer, F. J. A., Verburg, F. A., & Smits, M. (2022) · British Journal of Radiology · doi:10.1259/bjr.20211232 · Cited by 30
Reliable diagnosis of IDH-mutant glioblastoma by 2-hydroxyglutarate detection: a study by 3-T magnetic resonance spectroscopy
Natsumeda, M., Motohashi, K., Igarashi, H., Nozawa, T., Abe, H., Tsukamoto, Y., Ogura, R., Okada, M., Kobayashi, T., Aoki, H., et al. (2017) · Neurosurgical Review · doi:10.1007/s10143-017-0908-y · Cited by 29
Imaging Genomic Mapping in Glioblastoma
Zinn, P. O., & Colen, R. R. (2013) · Neurosurgery · doi:10.1227/01.neu.0000430773.18220.3f · Cited by 28
Accuracy of 2-hydroxyglutarate quantification by short-echo proton-MRS at 3 T: A phantom study
Bertolino, N., Marchionni, C., Ghielmetti, F., Burns, B. L., Finocchiaro, G., Anghileri, E., Bruzzone, M. G., & Minati, L. (2014) · Physica Medica · doi:10.1016/j.ejmp.2014.03.002 · Cited by 28
Extra-axial brain tumors
Rapalino, O., & Smirniotopoulos, J. G. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53485-9.00015-5 · Cited by 28
A comparison of 2‐hydroxyglutarate detection at 3 and 7 T with long‐TE semi‐LASER
Berrington, A., Voets, N., Larkin, S. J., de Pennington, N., McCullagh, J., Stacey, R. J., Schofield, C. J., Jezzard, P., Clare, S., Cadoux-Hudson, T. A. D., et al. (2018) · NMR in Biomedicine · doi:10.1002/nbm.3886 · Cited by 28
Metabolic Variations between Low-Grade and High-Grade GliomasProfiling by 1H NMR Spectroscopy
Jothi, J., Janardhanam, V. A., & Krishnaswamy, R. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00243 · Cited by 28
MR Molecular Imaging of Brain Cancer Metabolism Using Hyperpolarized 13C Magnetic Resonance Spectroscopy
Najac, C., & Ronen, S. M. (2016) · Topics in Magnetic Resonance Imaging · doi:10.1097/rmr.0000000000000104 · Cited by 27
A Comprehensive Review of Genomics and Noncoding RNA in Gliomas
Hassan, A. M., Mosley, J. C., Singh, S. K., & Zinn, P. O. (2017) · Topics in Magnetic Resonance Imaging · doi:10.1097/rmr.0000000000000111 · Cited by 28
Machine learning-based quantitative texture analysis of conventional MRI combined with ADC maps for assessment of IDH1 mutation in high-grade gliomas
Alis, D. C., Bağcılar, Ö., Senli, Y. D., Yergin, M., İşler, C., Koçer, N., Işlak, C., & Kızılkılıç, O. (2019) · Japanese Journal of Radiology · doi:10.1007/s11604-019-00902-7 · Cited by 27
A Noninvasive Comparison Study between Human Gliomas with IDH1 and IDH2 Mutations by MR Spectroscopy
Shen, X., Voets, N., Larkin, S. J., de Pennington, N., Stacey, R. J., Plaha, P., McCullagh, J., Schofield, C. J., Clare, S., Jezzard, P., et al. (2019) · Metabolites · doi:10.3390/metabo9020035 · Cited by 26
Imaging Genomics in Gliomas
Zinn, P. O., Mahmood, Z., Elbanan, M., & Colen, R. R. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000120 · Cited by 26
Radiological and Pathological Features Associated with IDH1-R132H Mutation Status and Early Mortality in Newly Diagnosed Anaplastic Astrocytic Tumours
Wasserman, J. K., Nicholas, G. A., Yaworski, R., Wasserman, A.-M., Woulfe, J., Jansen, G. H., Chakraborty, S., & Nguyen, T. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123890 · Cited by 26
In Vivo Modeling of Malignant Glioma
Kegelman, T. P., Hu, B., Emdad, L., Das, S. K., Sarkar, D., & Fisher, P. B. (2014) · Advances in cancer research · doi:10.1016/b978-0-12-800249-0.00007-x · Cited by 23
The Association between Whole‐Brain MR Spectroscopy and IDH Mutation Status in Gliomas
Goryawala, M., Lavi, E. S., Nagornaya, N., Heros, D. O., Komotar, R. J., & Maudsley, A. A. (2019) · Journal of Neuroimaging · doi:10.1111/jon.12685 · Cited by 25
Improved Localization for 2-Hydroxyglutarate Detection at 3 T Using Long-TE Semi-LASER
Berrington, A., Voets, N., Plaha, P., Larkin, S. J., McCullagh, J., Stacey, R. J., Yildirim, M., Schofield, C. J., Jezzard, P., Cadoux-Hudson, T. A. D., et al. (2016) · Tomography · doi:10.18383/j.tom.2016.00139 · Cited by 25
Cancer metabolism in a snapshot: MRS(I)
Julià‐Sapé, M., Candiota, A. P., & Arús, C. (2019) · NMR in Biomedicine · doi:10.1002/nbm.4054 · Cited by 25
Magnetic Resonance Spectroscopic Assessment of Isocitrate Dehydrogenase Status in Gliomas: The New Frontiers of Spectrobiopsy in Neurodiagnostics
Ieva, A. D., MAGNUSSEN, J. S., McIntosh, J., Mulcahy, M. J., Pardey, M. C., & Choi, C. (2019) · World Neurosurgery · doi:10.1016/j.wneu.2019.09.040 · Cited by 25
The Future of Glioma Treatment: Stem Cells, Nanotechnology and Personalized Medicine
Rahman, M., Hoh, B. L., Kohler, N., Dunbar, E. M., & Murad, G. J. A. (2012) · Future Oncology · doi:10.2217/fon.12.111 · Cited by 24
The role of 2-hydroxyglutarate magnetic resonance spectroscopy for the determination of isocitrate dehydrogenase status in lower grade gliomas versus glioblastoma: a systematic review and meta-analysis of diagnostic test accuracy
Bhandari, A., Sharma, C., Ibrahim, M. A., Riggs, M., Jones, R. E., & Lasocki, A. (2021) · Neuroradiology · doi:10.1007/s00234-021-02702-1 · Cited by 25
2-Hydroxyglutarate magnetic resonance spectroscopy in adult brainstem glioma
Iwahashi, H., Nagashima, H., Tanaka, K., Uno, T., Hashiguchi, M., Maeyama, M., Somiya, Y., Komatsu, M., Hirose, T., Itoh, T., et al. (2023) · Journal of neurosurgery · doi:10.3171/2022.12.jns221954 · Cited by 24
MRI-Based Deep Learning Method for Classification of IDH Mutation Status
Yogananda, C. G. B., Wagner, B., Truong, N. C. D., Holcomb, J. M., Reddy, D. D., Saadat, N., Hatanpaa, K. J., Patel, T., Fei, B., Lee, M., et al. (2023) · Bioengineering · doi:10.3390/bioengineering10091045 · Cited by 24
Rapid determination of isocitrate dehydrogenase mutation status of human gliomas by extraction nanoelectrospray using a miniature mass spectrometer
Pu, F., Alfaro, C. M., Pirro, V., Xie, Z., Ouyang, Z., & Cooks, R. G. (2019) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-019-01632-5 · Cited by 25
Characterization of cancer-associated IDH2 mutations that differ in tumorigenicity, chemosensitivity and 2-hydroxyglutarate production
Kotredes, K. P., Razmpour, R., Lutton, E. M., Alfonso‐Prieto, M., Ramirez, S. H., & Gamero, A. M. (2019) · Oncotarget · doi:10.18632/oncotarget.26848 · Cited by 24
Early Noninvasive Metabolic Biomarkers of Mutant IDH Inhibition in Glioma
Radoul, M., Hong, D., Gillespie, A. M., Najac, C., Viswanath, P., Pieper, R. O., Costello, J., Luchman, H. A., & Ronen, S. M. (2021) · Metabolites · doi:10.3390/metabo11020109 · Cited by 24
Magnetic resonance spectroscopy of isocitrate dehydrogenase mutated gliomas: current knowledge on the neurochemical profile
Branzoli, F., & Marjańska, M. (2020) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000833 · Cited by 23
Molecular, histopathological, and genomic variants of glioblastoma
Karsy, M. J. (2014) · Frontiers in bioscience · doi:10.2741/4268 · Cited by 23
Clinical Implications of Molecular Neuropathology and Biomarkers for Malignant Glioma
Tabatabai, G., Hegi, M. E., Stupp, R., & Weller, M. (2012) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-012-0263-x · Cited by 23
Impacts of MR spectroscopic imaging on glioma patient management
Chronaiou, I., Stensjøen, A. L., Sjøbakk, T. E., Esmaeili, M., & Bathen, T. F. (2014) · Acta Oncologica · doi:10.3109/0284186x.2014.891046 · Cited by 23
Classification of brain tumours from MR spectra: the INTERPRET collaboration and its outcomes
Julià‐Sapé, M., Griffiths, J. R., Tate, A. R., Howe, F. A., Acosta, D., Postma, G., Underwood, J., Majós, C., & Arús, C. (2015) · NMR in Biomedicine · doi:10.1002/nbm.3439 · Cited by 23
Emerging Approaches for Targeting Metabolic Vulnerabilities in Malignant Glioma
Clark, P. M., Mai, W. X., Cloughesy, T. F., & Nathanson, D. A. (2016) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-015-0613-6 · Cited by 21
Self-citation
Multi-tracer and multiparametric PET imaging to detect the IDH mutation in glioma: a preclinical translational in vitro, in vivo, and ex vivo study
Clément, A., Zaragori, T., Filosa, R., Ovdiichuk, O. V., Beaumont, M., Collet, C., Roeder, E., Martin, B., Maskali, F., Barberi‐Heyob, M., et al. (2022) · Cancer Imaging · doi:10.1186/s40644-022-00454-6 · Cited by 19
Blood-brain barrier disruption defines the extracellular metabolome of live human high-grade gliomas
Riviere-Cazaux, C., Carlstrom, L. P., Rajani, K. R., Munoz-Casabella, A., Rahman, M., Loron, A. G., Brown, D. A., Miller, K. J., White, J. J., Himes, B. T., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-05035-2 · Cited by 20
Combined texture analysis of diffusion-weighted imaging with conventional MRI for non-invasive assessment of IDH1 mutation in anaplastic gliomas
Su, C., Lu, S., Zhou, M.-D., Shen, H., Shi, H., & Hong, X. (2018) · Clinical Radiology · doi:10.1016/j.crad.2018.10.002 · Cited by 20
An artificial intelligence method to assess the tumor microenvironment with treatment outcomes for gastric cancer patients after gastrectomy
Chen, T., Li, X., Mao, Q., Wang, Y., Li, H., Wang, C., Shen, Y., Guo, E., He, Q., Tian, J., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03298-7 · Cited by 20
Intra-axial brain tumors
Rapalino, O., Batchelor, T. T., & González, R. G. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53485-9.00014-3 · Cited by 20
In vivo 2-hydroxyglutarate-proton magnetic resonance spectroscopy (3 T, PRESS technique) in treatment-naïve suspect lower-grade gliomas: feasibility and accuracy in a clinical setting
Cuccarini, V., Antelmi, L., Pollo, B., Paterra, R., Calatozzolo, C., Nigri, A., DiMeco, F., Eoli, M., Finocchiaro, G., Brenna, G., et al. (2019) · Neurological Sciences · doi:10.1007/s10072-019-04087-9 · Cited by 18
Potential implications of hydrogen peroxide in the pathogenesis and therapeutic strategies of gliomas
Zhou, Y., Wang, L., Wang, C., Wu, Y., Chen, D., & Lee, T. H. (2020) · Archives of Pharmacal Research · doi:10.1007/s12272-020-01205-6 · Cited by 19
Radiogenomic Predictors of Recurrence in Glioblastoma—A Systematic Review
Corr, F., Grimm, D., Saß, B., Pojskić, M., Bartsch, J. W., Carl, B., Nimsky, C., & Bopp, M. H. A. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030402 · Cited by 25
Imaging Genomics of Glioblastoma
Moton, S., Elbanan, M., Zinn, P. O., & Colen, R. R. (2015) · Topics in Magnetic Resonance Imaging · doi:10.1097/rmr.0000000000000052 · Cited by 18
Rapid detection of mutation in isocitrate dehydrogenase 1 and 2 genes using mass spectrometry
Kanamori, M., Maekawa, M., Shibahara, I., Saito, R., Chonan, M., Shimada, M., Sonoda, Y., Kumabe, T., Watanabe, M., Mano, N., et al. (2018) · Brain Tumor Pathology · doi:10.1007/s10014-018-0317-0 · Cited by 17
Spectroscopic imaging of D-2-hydroxyglutarate and other metabolites in pre-surgical patients with IDH-mutant lower-grade gliomas
Autry, A. W., Lafontaine, M., Jalbert, L. E., Phillips, E. J., Phillips, J. J., Villanueva-Meyer, J. E., Berger, M. S., Chang, S. M., & Li, Y. (2022) · Journal of Neuro-Oncology · doi:10.1007/s11060-022-04042-3 · Cited by 17
Emerging MR Imaging and Spectroscopic Methods to Study Brain Tumor Metabolism
Kumar, M., Nanga, R. P. R., Verma, G., Wilson, N. E., Brisset, J., Nath, K., & Chawla, S. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.789355 · Cited by 16
Self-citation
Radiogenomics of Gliomas
Badve, C. A., & Kanekar, S. G. (2021) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2021.02.002 · Cited by 15
Research of Pesticide Metabolites in Human Brain Tumor Tissues by Chemometrics-Based Gas Chromatography–Mass Spectrometry Analysis for a Hypothetical Correlation between Pesticide Exposure and Risk Factor of Central Nervous System Tumors
Louati, K., Kolsi, F., Kallel, R., Gdoura, Y., Borni, M., Hakim, L. S., Zribi, R., Choura, S., Maalej, A., Sayadi, S., et al. (2023) · ACS Omega · doi:10.1021/acsomega.3c04592 · Cited by 15
GSH and GABA decreases in IDH1-mutated low-grade gliomas detected by HERMES spectral editing at 3 T in vivo
Gong, T., Zhang, X., Wei, X., Yuan, S., Saleh, M. G., Song, Y., Edden, R. A. E., & Wang, G. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104889 · Cited by 15
Mitochondrial substrates in cancer: Drivers or passengers?
Kruspig, B., Zhivotovsky, B., & Gogvadze, V. G. (2014) · Mitochondrion · doi:10.1016/j.mito.2014.08.007 · Cited by 15
2-Hydroxyglutarate Detection by Short Echo Time Magnetic Resonance Spectroscopy in Routine Imaging Study of Brain Glioma at 3.0 T
Crisi, G., Filice, S., Michiara, M., Crafa, P., & Lana, S. (2017) · Journal of Computer Assisted Tomography · doi:10.1097/rct.0000000000000705 · Cited by 15
An Enzymatic Biosensor for the Detection of D-2-Hydroxyglutaric Acid in Serum and Urine
Wu, B., Li, Z., Kang, Z., Ma, C., Song, H., Lu, F., & Zhu, Z. (2022) · Biosensors · doi:10.3390/bios12020066 · Cited by 15
Scientific and Clinical Challenges within Neuro-Oncology
Barbaro, M., Fine, H. A., & Magge, R. (2021) · World Neurosurgery · doi:10.1016/j.wneu.2021.01.151 · Cited by 15
Rapid detection of isocitrate dehydrogenase 1 mutation status in glioma based on Crispr-Cas12a
Feng, Z., Kong, D., Jin, W., He, K., Zhao, J.-Y., Liu, B., Xu, H., Yu, X., & Feng, S. (2023) · Scientific Reports · doi:10.1038/s41598-023-32957-y · Cited by 14
2‐Hydoxyglutarate: D/Riving Pathology in gLiomaS
Wahl, D. R., & Venneti, S. (2015) · Brain Pathology · doi:10.1111/bpa.12309 · Cited by 14
Maternal high-fat diet changes DNA methylation in the early embryo by disrupting the TCA cycle intermediary alpha ketoglutarate
Penn, A., McPherson, N. O., Fullston, T., Arman, B. M., & Zander‐Fox, D. (2023) · Reproduction · doi:10.1530/rep-22-0302 · Cited by 14
Correlations Between DTI-derived Metrics and MRS Metabolites in Tumour Regions of Glioblastoma: A Pilot Study
Flores-Álvarez, E., Piedra, E. A. R., Cruz-Priego, G.-A., Durand-Muñoz, C., Moreno-Jimenez, S., & Roldán-Valadez, E. (2020) · Radiology and Oncology · doi:10.2478/raon-2020-0055 · Cited by 11
Prediction of Glioma Stemlike Cell Infiltration in the Non–Contrast-Enhancing Area by Quantitative Measurement of Lactate on Magnetic Resonance Spectroscopy in Glioblastoma
Inoue, A., Nishikawa, M., Ohnishi, T., Yano, H., Kanemura, Y., Ohtsuka, Y., Ozaki, S., Nakamura, Y., Matsumoto, S., Suehiro, S., et al. (2021) · World Neurosurgery · doi:10.1016/j.wneu.2021.06.044 · Cited by 15
1.5 vs 3 Tesla Magnetic Resonance Imaging
Radbruch, A., Paech, D., Gassenmaier, S., Luetkens, J. A., Isaak, A., Herrmann, J., Othman, A. E., Schäfer, J. F., & Nikolaou, K. (2021) · Investigative Radiology · doi:10.1097/rli.0000000000000818 · Cited by 14
Spectral fitting strategy to overcome the overlap between 2‐hydroxyglutarate and lipid resonances at 2.25 ppm
Askari, P., Dimitrov, I. E., Ganji, S., Tiwari, V., Levy, M. L., Patel, T., Pan, E., Mickey, B., Malloy, C. R., Maher, E. A., et al. (2021) · Magnetic Resonance in Medicine · doi:10.1002/mrm.28829 · Cited by 13
Preoperative Determination of Isocitrate Dehydrogenase Mutation in Gliomas Using Spectral Editing MRS : A Prospective Study
Nguyen, T., Melkus, G., Taccone, M. S., Moldovan, I. D., Ghinda, D., Gotfrit, R., Torres, C., Zakhari, N., Chakraborty, S., Woulfe, J., et al. (2020) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.27366 · Cited by 13
The Distribution and Significance of IDH Mutations in Gliomas
Mellai, M., Caldera, V., Annovazzi, L., & Schiffer, D. (2013) · InTech eBooks · doi:10.5772/52357 · Cited by 14
Incorporation of Edited MRS into Clinical Practice May Improve Care of Patients with IDH -Mutant Glioma
Nichelli, L., Cadin, C., Lazzari, P., Mathon, B., Touat, M., Sanson, M., Bielle, F., Marjańska, M., Lehéricy, S., & Branzoli, F. (2024) · American Journal of Neuroradiology · doi:10.3174/ajnr.a8413 · Cited by 12
On the Utility of Short Echo Time (TE) Single Voxel 1H–MRS in Non–Invasive Detection of 2–Hydroxyglutarate (2HG); Challenges and Potential Improvement Illustrated with Animal Models Using MRUI and LCModel
Heo, H., Kim, S., Lee, H. H., Cho, H. R., Xu, W. J., Lee, S., Park, C., Park, S., Choi, S. H., & Kim, H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147794 · Cited by 12
Iron-induced epigenetic abnormalities of mouse bone marrow through aberrant activation of aconitase and isocitrate dehydrogenase
Yamamoto, M., Tanaka, H., Toki, Y., Hatayama, M., Ito, S., Addo, L., Shindo, M., Sasaki, K., Ikuta, K., Ohtake, T., et al. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2054-7 · Cited by 12
Molecular characteristics of diffuse lower grade gliomas: what neurosurgeons need to know
Young, J. S., Gogos, A., Morshed, R. A., Hervey‐Jumper, S. L., & Berger, M. S. (2020) · Acta Neurochirurgica · doi:10.1007/s00701-020-04426-2 · Cited by 11
IDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma
Yao, Y. (2014) · Medical Science Monitor · doi:10.12659/msm.889891 · Cited by 11
Pheochromocytoma/Paraganglioma: A Poster Child for Cancer Metabolism
Tevosian, S. G., & Ghayee, H. K. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01991 · Cited by 11
Multiparameter quantitative histological MRI values in high-grade gliomas: a potential biomarker of tumor progression
Reuter, G., Lommers, É., Balteau, E., Simon, J., Phillips, C. L. M., Scholtes, F., Martin, D., Lombard, A., & Maquet, P. (2020) · Neuro-Oncology Practice · doi:10.1093/nop/npaa047 · Cited by 11
The role and potential of using quantitative MRI biomarkers for imaging guidance in brain cancer radiotherapy treatment planning: A systematic review
Aldawsari, A., Al‐Qaisieh, B. M., Broadbent, D. A., Bird, D., Murray, L. J., & Speight, R. J. (2023) · Physics and Imaging in Radiation Oncology · doi:10.1016/j.phro.2023.100476 · Cited by 11
Fractal dimension and lacunarity measures of glioma subcomponents are discriminative of the grade of gliomas and IDH status
Yadav, N., Mohanty, A., Aswin, V., & Tiwari, V. (2024) · NMR in Biomedicine · doi:10.1002/nbm.5272 · Cited by 10
Evolution of Molecular Biomarkers and Precision Molecular Therapeutic Strategies in Glioblastoma
Jacome, M. A., Wu, Q., Piña, Y., & Etame, A. B. (2024) · Cancers · doi:10.3390/cancers16213635 · Cited by 11
Isocitrate dehydrogenase 1 mutation in cholangiocarcinoma impairs tumor progression by sensitizing cells to ferroptosis
Su, L., Huang, Y., Zheng, L., Zhu, Z., Wu, Y., & Li, P. (2022) · Open Medicine · doi:10.1515/med-2022-0477 · Cited by 10

Authors: Pope, W. B., Prins, R. M., Albert Thomas, M., Nagarajan, R., Yen, K. E., Bittinger, M. A., Salamon, N., Chou, A. P., Yong, W. H., Soto, H., Wilson, N., Driggers, E., Jang, H. G., Su, S. M., Schenkein, D. P., Lai, A., Cloughesy, T. F., Kornblum, H. I., Wu, H., Fantin, V. R., & Liau, L. M.
Affiliations: University of California, Los Angeles (US)
Agios Pharmaceuticals (United States) (US)
Corresponding author: Liau, Linda M.
ORCID: Pope, Whitney B.
Prins, Robert M.
Nagarajan, Rajakumar
Yen, Katharine E.
Salamon, Noriko
Yong, William H.
Wilson, Neil
Jang, Hyun G.
Lai, Albert
Cloughesy, Timothy F.
Kornblum, Harley I.
Wu, Hong
Fantin, Valeria R.
Liau, Linda M.
Venue: Journal of Neuro-Oncology
Publisher: Springer Science and Business Media LLC
Published: 2011-10-21
Volume: 107
Issue: 1
Pages: 197-205
ISSN: 0167-594X (ISSN-L)
1573-7373
DOI: 10.1007/s11060-011-0737-8
PMC: PMC3650613
OpenAlex: W2083820071
Cited by: 318
References: 32
Citations by year: 2026: 14 · 2025: 8 · 2024: 12 · 2023: 22 · 2022: 15 · 2021: 23 · 2020: 26 · 2019: 27 · 2018: 27 · 2017: 32 · 2016: 29 · 2015: 27 · 2014: 24 · 2013: 17 · 2012: 13
FWCI: 8.64
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Journal of Neuro-Oncology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (UL1TR000124)
National Cancer Institute (R01CA121131, R01CA123396, K01CA111402, R01CA112358)
National Institute of Neurological Disorders and Stroke (R01NS052563)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Advanced MRI Techniques and Applications
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
Keywords: 2-hydroxyglutarate, IDH1 mutation, glioma, oncometabolites, magnetic resonance spectroscopy, non-invasive cancer detection, choline, glutathione, Ki-67 proliferation index, tumor metabolites, biomarkers
MeSH terms: Adult, Aged, Aged, 80 and over, Brain Neoplasms, Chromatography, Liquid, DNA, Neoplasm, Female, Follow-Up Studies, Glioma, Glutarates, Humans, Isocitrate Dehydrogenase, Magnetic Resonance Imaging, Male, Middle Aged, Mutation, Magnetic Resonance Spectroscopy, Prognosis, Prospective Studies, Mass Spectrometry, Biomarkers, Tumor, Polymerase Chain Reaction, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks